Latest Breaking News On - Merck sharp dohme - Page 1 : comparemela.com

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

/PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in.

United statesJoe fletcherDavid hymanPrnewswire eli lillyEli lillyTimothy burnsExchange commissionAmerican society of clinical oncologyMerck sharp dohmeLilly united statesMerck co incCancer researchClinical oncologyAssociate professorPittsburgh medical center hillman cancerMerck sharp

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Foster cityUnited statesUnited arab emiratesLuis pazMerdad parseyEuropean unionHead of the medical oncology serviceGilead sciencesAmerican society of clinical oncologyGilead sciences incMerck co incMerck sharp dohmeExchange commissionClinical oncologyLuis paz aresMedical oncology service

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesChristina cameronSuperkine immunotherapiesPembrolizumab keytrudaMerck sharp dohmeSafety review committeeMerck co incOncology innovation forumMedicenna therapeutics corpDurable single agent activityPotent immune effector responseDose escalation portionAnnual oncology innovationAnnual oncology innovation forumFahar merchantOrphan drug

Anaveon announces IND approval of ANV600-001 Phase I/II clinical study

Anaveon announces IND approval of ANV600-001 Phase I/II clinical study
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesEduard gasalJulia wilsonMerck co incMerck sharp dohmeInvestigational new drugChief medical officerNews publishing

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEduard gasalJulia wilsonMerck sharp dohmeMerck co incJw communicationsInvestigational new drugChief medical officerMerck sharp